<DOC>
	<DOC>NCT00388206</DOC>
	<brief_summary>This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in combination with first-line chemotherapy. Second-line metastatic CRC patients are also eligible. Patients who started their Avastin containing therapy &lt;4 months prior to enrollment are eligible.</brief_summary>
	<brief_title>A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed Informed Consent Form Metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) Eligible for Avastin as a component of intended therapy Firstline chemotherapy (or secondline chemotherapy for CRC) plus Avastin initiated â‰¤ 4 months prior to study enrollment Any medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to provide informed consent or comply with the treatment and followup, as specified by the investigator Enrollment in a blinded, placebocontrolled bevacizumab trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Avastin</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>lung cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>ARIES</keyword>
	<keyword>Colon Cancer</keyword>
</DOC>